{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1364233269583957504.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.1002/hep.510300313"}},{"identifier":{"@type":"URI","@value":"https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fhep.510300313"}},{"identifier":{"@type":"URI","@value":"https://journals.lww.com/01515467-199909000-00023"}},{"identifier":{"@type":"NAID","@value":"30015135345"}}],"dc:title":[{"@value":"Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B"}],"description":[{"type":"abstract","notation":[{"@value":"<jats:sec>\n            <jats:title/>\n            <jats:p>In the reported Asian lamivudine trial, the rate of hepatitis B e antigen (HBeAg) seroconversion, defined as HBeAg/hepatitis B virus (HBV) DNA seroclearance and development of anti-HBe, during 52 weeks of treatment was only 13% to 16%. To evaluate whether any factors influenced HBeAg seroconversion, data from 345 patients in that trial were reanalyzed to correlate HBeAg seroconversion with variables including treatment, age, gender, body build, histology, baseline HBV-DNA levels, and alanine transaminase (ALT) levels. Exploratory analysis using stepwise modeling revealed that HBeAg seroconversion correlated highly with pretherapy ALT (<jats:italic toggle=\"yes\">P</jats:italic>< .001) followed by lamivudine therapy (<jats:italic toggle=\"yes\">P</jats:italic>= .013), but only marginally with baseline HBV-DNA (<jats:italic toggle=\"yes\">P</jats:italic>= .071) and cirrhosis (<jats:italic toggle=\"yes\">P</jats:italic>= .066) for lamivudine 100 mg and placebo comparison. Among these four variables, only pretherapy ALT still had a highly significant (<jats:italic toggle=\"yes\">P</jats:italic>< .001) correlation and lamivudine therapy had a borderline association (<jats:italic toggle=\"yes\">P</jats:italic>= .066) for lamivudine 25 mg and placebo comparison. Categorical analysis revealed that HBeAg seroconversion occurred earlier and the cumulative rate was significantly higher in patients with pretherapy ALT values over 2 times the upper limit of normal (ULN) as compared with treated patients with lower ALT levels or untreated control patients with the same ALT levels (<jats:italic toggle=\"yes\">P</jats:italic>< .001, respectively). The highest HBeAg seroconversion rate was observed in 100 mg lamivudine-treated patients with ALT levels greater than 5 times the ULN (64%) compared with patients with ALT 2 to 5 times the ULN (26%,<jats:italic toggle=\"yes\">P</jats:italic>= .03); and ALT less than 2 times the ULN, (5%,<jats:italic toggle=\"yes\">P</jats:italic>< .001). These results suggest that pretherapy ALT is the strongest determinant for HBeAg seroconversion during lamivudine therapy, and should be considered in selecting patients for treatment.</jats:p>\n          </jats:sec>"}]}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1384233269583957506","@type":"Researcher","foaf:name":[{"@value":"Rong-Nan Chien"}]},{"@id":"https://cir.nii.ac.jp/crid/1384233269583957504","@type":"Researcher","foaf:name":[{"@value":"Yun-Fan Liaw"}]},{"@id":"https://cir.nii.ac.jp/crid/1384233269583957505","@type":"Researcher","foaf:name":[{"@value":"Mark Atkins"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"02709139"},{"@type":"PISSN","@value":"http://id.crossref.org/issn/02709139"}],"prism:publicationName":[{"@value":"Hepatology"}],"dc:publisher":[{"@value":"Ovid Technologies (Wolters Kluwer Health)"}],"prism:publicationDate":"1999-09","prism:volume":"30","prism:number":"3","prism:startingPage":"770","prism:endingPage":"774"},"reviewed":"false","dc:rights":["http://doi.wiley.com/10.1002/tdm_license_1.1"],"url":[{"@id":"https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fhep.510300313"},{"@id":"https://journals.lww.com/01515467-199909000-00023"}],"createdAt":"2004-07-28","modifiedAt":"2024-12-01","relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1360565168116348928","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"JSH Guidelines for the Management of Hepatitis B Virus Infection"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001204241440384","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Lamivudine as an Alternative Therapy for Interferon-Resistant Chronic Hepatitis B and the Characteristics of Hepatitis B Virus: A Case Report"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001204792496896","@type":"Article","relationType":["isCitedBy"],"jpcoar:relatedTitle":[{"@value":"慢性Ｂ型肝炎に対するラミブジン治療"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001204792869120","@type":"Article","relationType":["isReferencedBy","isCitedBy"],"jpcoar:relatedTitle":[{"@language":"ja","@value":"B型慢性肝炎に対するラミブジン投与時のYMDD変異株出現例と非出現例での real time PCRによるウイルス動態の検討"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282679769900032","@type":"Article","relationType":["isReferencedBy","isCitedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Renal dysfunction in chronic hepatitis B patients treated with adefovir dipivoxil"},{"@language":"ja","@value":"アデホビルによる腎障害の検討"},{"@language":"ja-Kana","@value":"アデホビル ニ ヨル ジン ショウガイ ノ ケントウ"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282679771619840","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Two cases of acute hepatitis due to hepatitis E virus that are indigenous to Kitakyushu: a case report"},{"@language":"ja","@value":"北九州に土着したE型肝炎ウイルス株による急性肝炎の2例"},{"@value":"B型肝炎治療ガイドライン(第1.1版)"},{"@language":"ja-Kana","@value":"Bガタ カンエン チリョウ ガイドライン(ダイ1.1ハン)"},{"@language":"ja-Kana","@value":"キタキュウシュウ ニ ドチャク シタ Eガタ カンエンウイルスカブ ニ ヨル キュウセイ カンエン ノ 2レイ"},{"@value":"Guidelines for the management of hepatitis B virus infection"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282681372151296","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isCitedBy"],"jpcoar:relatedTitle":[{"@value":"慢性肝炎の抗ウイルス療法　　Ｂ型慢性肝炎"},{"@language":"en","@value":"Chronic hepatitis B"}]},{"@id":"https://cir.nii.ac.jp/crid/1570009749780572160","@type":"Article","relationType":["isCitedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Efficacy and tolerability of long-term therapy using high lamivudine doses for the treatment of chronic hepatitis B"}]},{"@id":"https://cir.nii.ac.jp/crid/1570009750285604864","@type":"Article","relationType":["isCitedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Update of research and management of hepatitis B"}]},{"@id":"https://cir.nii.ac.jp/crid/1570009750587273344","@type":"Article","relationType":["isCitedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Lamivudine treatment in maternally transmitted chronic hepatitis B virus infection patients"}]},{"@id":"https://cir.nii.ac.jp/crid/1570009751290898816","@type":"Article","relationType":["isCitedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Correlation of YMDD mutation and breakthrough hepatitis with hepatitis B virus DNA and serum ALT during lamivudine treatment"}]},{"@id":"https://cir.nii.ac.jp/crid/1573668925238411392","@type":"Article","relationType":["isCitedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Factors associated with the virological response of lamivudine-resistant hepatitis B virus during combination therapy with adefovir dipivoxil plus lamivudine"}]},{"@id":"https://cir.nii.ac.jp/crid/1573668926519536128","@type":"Article","relationType":["isCitedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Treatment of hepatitis B"}]},{"@id":"https://cir.nii.ac.jp/crid/1573950399994458240","@type":"Article","relationType":["isCitedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Lamivudine as an Alternative Therapy for Interferon-Resistant Chronic Hepatitis B and the Characteristics of Hepatitis B Virus : A Case Report"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1002/hep.510300313"},{"@type":"CIA","@value":"30015135345"},{"@type":"CROSSREF","@value":"10.2957/kanzo.43.214_references_DOI_5P0vXirSVqXroYGqEBVeiXKqILw"},{"@type":"CROSSREF","@value":"10.1620/tjem.191.247_references_DOI_5P0vXirSVqXroYGqEBVeiXKqILw"},{"@type":"CROSSREF","@value":"10.1111/hepr.12269_references_DOI_5P0vXirSVqXroYGqEBVeiXKqILw"},{"@type":"CROSSREF","@value":"10.2957/kanzo.52.102_references_DOI_5P0vXirSVqXroYGqEBVeiXKqILw"},{"@type":"CROSSREF","@value":"10.2957/kanzo.54.402_references_DOI_5P0vXirSVqXroYGqEBVeiXKqILw"}]}